BofA raises Ligand Pharma stock price target on XOMA acquisition

BofA raised Ligand Pharmaceuticals’ price target to $260 from $250 and kept a Buy rating, citing the $739 million XOMA acquisition plus CVR as a portfolio-expanding deal that adds roughly 120 programs, including 7 commercial assets and 14 late-stage programs. The company also reported Q4 revenue of $59.7 million versus $55.6 million expected and adjusted EPS of $2.02 versus $1.50 expected, with full-year adjusted EPS of $8.13. The stock has already returned 114% over the past year and 22% year to date, but shares remain near highs and are viewed as overvalued relative to fair value.

Analysis

LGND is becoming less of a pure royalty compounder and more of a quasi-capital-allocation vehicle with embedded duration. The XOMA deal likely matters more for financing optionality than for near-term earnings: by adding diversified late-stage assets and commercial cash flows, management is effectively smoothing royalty volatility, which should support a higher multiple if execution remains clean. The second-order effect is that the market may start valuing LGND less like a single-name biotech royalty stream and more like a scaled royalty platform, but that only holds if integration does not dilute ROIC.

The key risk is not the headline premium, but the market’s willingness to underwrite acquisition-driven growth after a large, somewhat complex transaction. If the CVR or funding mix creates leverage creep or delays in closing, the stock can de-rate quickly because the current valuation already embeds a lot of optimism. The next 3-6 months likely trade on deal certainty and management’s ability to quantify accretion, while the 12-24 month outcome depends on whether the added programs actually convert into durable royalty cash flows rather than just portfolio breadth.

The most interesting contrarian point is that the crowd may be overpaying for diversification at the exact point where quality of earnings matters most. A broader royalty book helps headline stability, but it can also lower the scarcity value of LGND if investors conclude the company is simply buying growth rather than compounding proprietary economics. The cleaner expression may be to own the acquirer only on dips and look for any post-announcement enthusiasm in the target or adjacent royalty names to fade once the market focuses on execution risk and financing structure.

TVTX is a quieter beneficiary because FILSPARI royalty economics become more visible inside a larger platform, which can support sentiment around asset durability and future royalty expansion. The flip side is that any slowdown in FILSPARI uptake would be disproportionately damaging to the “portfolio expansion” narrative, since the market is currently rewarding LGND for breadth rather than pure concentration. That creates a setup where good news can lift the stock modestly, but any stumble in the next two quarters can unwind a lot of the recent re-rating.

Key Decisions for Investors

• Buy LGND on pullbacks below the post-deal enthusiasm zone with a 3-6 month horizon; upside is continued multiple expansion if accretion is clearly communicated, but stop out if leverage/funding terms look dilutive or close drift extends.
• Use LGND call spreads rather than outright equity for a 3-6 month catalyst window; the skew favors upside on deal approval/financing clarity, while capping premium paid against a valuation reset.
• Pair long LGND / short a basket of weaker, more concentrated royalty names over 6-12 months; LGND’s diversification story should attract premium capital if execution is solid, while single-asset peers are more exposed to idiosyncratic royalty misses.
• Do not chase XOMAP upside after the announced premium unless the market assigns material probability to competing bids; the spread should compress as closing certainty improves, so the risk/reward is asymmetric only for event-driven arbitrage, not directional longs.
• Monitor TVTX into the next royalty print as a secondary read-through on FILSPARI durability; if uptake accelerates, it strengthens LGND’s strategic narrative, but if growth stalls, reduce LGND exposure because the market is implicitly paying for a diversified-growth story.